^
Association details:
| Biomarker: | FOLH1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | voxalatamab (JNJ-63898081) (CD3 agonist, PSMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Functional Characterization of a Novel PSMA/CD3 Redirection Molecule for the Treatment of Prostate Cancer
Published date:
10/10/2020
Excerpt:
JNJ-63898081 induced antigen dependent cytotoxicity across a panel of PSMA expressing cell lines varying in PSMA expression (20,000 to 150,000 copies/cell). JNJ-63898081 incubated in vitro with patient derived and healthy donor derived T cells were equally effective at eliminating PSMA expressing tumor cells. In addition, JNJ-63898081 was able to effectively cause T cell dependent cytotoxicity of an enzalutamide-resistant LNCaP-AR cell line.
